Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Warner Chilcott, a specialty pharmaceutical company, has signed an agreement with Dong-A PharmTech based in Korea, to develop and market its orally-administered udenafil product, a phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction in the US. Dong-A has successfully completed Phase II studies of the product in the US.
Subscribe to our email newsletter
Under the terms of the agreement, Warner Chilcott has exclusive US rights to develop and market the product for the treatment of erectile dysfunction (ED). Dong-A will receive an initial, up-front payment and may also be eligible to receive additional payments upon achievement of certain milestones.
The product was approved by the Korean Food and Drug Administration in December of 2005 for the treatment of ED in Korea under the brand name Zydena. The product was also approved in Russia in July of 2008.